<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To determine the prognosis of patients with symptomatic intracranial <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> who fail antithrombotic therapy </plain></SENT>
<SENT sid="1" pm="."><plain>BACKGROUND: The outcome of patients with symptomatic intracranial <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> who fail antithrombotic therapy is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>These patients may represent the target group for investigation of more aggressive therapies such as intracranial angioplasty </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The authors performed a chart review and telephone interview of patients with symptomatic intracranial <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> identified in the Stanford <z:hpo ids='HP_0001297'>Stroke</z:hpo> Center clinical database </plain></SENT>
<SENT sid="4" pm="."><plain>A Cox regression model was created to identify factors predictive of failure of antithrombotic therapy </plain></SENT>
<SENT sid="5" pm="."><plain>The authors generated Kaplan-Meier survival curves to determine the timing of recurrent <z:hpo ids='HP_0002326'>TIA</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, or <z:hpo ids='HP_0011420'>death</z:hpo> after failure of antithrombotic therapy </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Fifty-two patients had symptomatic intracranial <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and fulfilled entry criteria </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-nine of the 52 patients (55.8%) had cerebral ischemic events while receiving an antithrombotic agent (antiplatelet agents [55%], <z:chebi fb="8" ids="10033">warfarin</z:chebi> [31%], or <z:chebi fb="5" ids="28304">heparin</z:chebi> [14%]) </plain></SENT>
<SENT sid="8" pm="."><plain>In a Cox regression model, older age was an independent predictor of failure of antithrombotic therapy, and <z:chebi fb="8" ids="10033">warfarin</z:chebi> use was associated with a decrease in risk </plain></SENT>
<SENT sid="9" pm="."><plain>Recurrent <z:hpo ids='HP_0002326'>TIA</z:hpo> (n = 7), nonfatal/fatal <z:hpo ids='HP_0001297'>stroke</z:hpo> (n = 6/1), or <z:hpo ids='HP_0011420'>death</z:hpo> (n = 1) occurred in 15 of 29 (51.7%) of the patients who failed antithrombotic therapy </plain></SENT>
<SENT sid="10" pm="."><plain>The median time to recurrent <z:hpo ids='HP_0002326'>TIA</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, or <z:hpo ids='HP_0011420'>death</z:hpo> was 36 days (95% CI 13 to 59) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Patients with symptomatic intracranial <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> who fail antithrombotic therapy have extremely high rates of recurrent <z:hpo ids='HP_0002326'>TIA</z:hpo>/<z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Recurrent ischemic events typically occur within a few months after failure of standard medical therapy </plain></SENT>
<SENT sid="13" pm="."><plain>The high recurrence risk observed warrants testing of alternative treatment strategies such as intracranial angioplasty </plain></SENT>
</text></document>